During the past decade, Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "AIO-Studien-gGmbH" with 2 trials sponsored, "Actelion" with 2 trials sponsored, "BioNTech Cell & Gene Therapies GmbH" with 1 trials sponsored and "Doasense GmbH" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Clinical Research Services, Mannheim, Germany" with 1 trials as a collaborator, "Deutsche Krebshilfe e.V., Bonn (Germany)" with 1 trials as a collaborator, "Institute Medical Statistics, Medical Faculty Mannheim" with 1 trials as a collaborator and "Medical Care Center Dr. Limbach and Colleagues, Heidelberg, Germany" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" are "Bladder Cancer" (3 trials), "Pulmonary Arterial Hypertension" (2 trials), "Adenocarcinoma Gastric" (1 trials), "Anticoagulant Therapy" (1 trials) and "Chemo-refractory Colorectal Carcinoma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" are "Drug" (8 trials), "Biological" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Alectinib" (1 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Belvarafenib" (1 trials) and "CLDN6 CAR-T/CLDN6 CAR-T(A)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".